去甲氧柔红霉素、柔红霉素分别联合阿糖胞苷诱导治疗初治成人急性髓系白血病的疗效及预后分析  

Effect and Prognosis of Idarubicin and Daunorubicin Respectively Combined with Cytarabine in Induction Treatment of Newly-Treated Adults with Acute Myeloid Leukemia

作　　者：张露雅 ZHANG Lu-ya(Department of Hematology,Nanyang Central Hospital,Nanyang 473000,Henan Province,China)

机构地区：[1]河南省南阳市中心医院血液内科,河南南阳473000

出　　处：《罕少疾病杂志》2022年第7期107-109,共3页Journal of Rare and Uncommon Diseases

摘　　要：目的探讨去甲氧柔红霉素、柔红霉素分别联合阿糖胞苷诱导治疗初治成人急性髓系白血病的疗效及预后。方法选取2018年1月至2020年1月在本院确诊的初治成人急性髓系白血病患者82例,采用简单随机分组将患者分为治疗组和对照组,每组各41例。对照组患者采用柔红霉素联合阿糖胞苷治疗,治疗组采用去甲氧柔红霉素联合阿糖胞苷治疗,均持续治疗3周。治疗后比较两组疗效以及不良反应,随访1年观察生存以及复发情况。结果治疗组患者治疗的有效率为75.60%,明显高于对照组患者治疗的53.65%(P<0.05);治疗组患者治疗期间的不良反应发生率与对照组患者无显著差异(P>0.05);治疗组治疗半年和1年的生存率为的87.80%和60.97%,与对照组治疗的70.73%和51.21%无显著差异(P>0.05),治疗组治疗1年的复发率为17.07%,明显高于低于对照组的36.58%(P<0.05)。结论去甲氧柔红霉素联合阿糖胞苷治疗可以明显提高成人急性髓系白血病患者的临床疗效,同时降低复发率,且安全性较好。Objective To explore the effect and prognosis of idarubicin and daunorubicin respectively combined with cytarabine in induction treatment of newly-treated adults with acute myeloid leukemia(AML).Methods A total of 82 newly-treated adults confirmed with AML in the hospital from January 2018 to January 2020 were enrolled and divided into treatment group and control group by simple random grouping method,41 cases in each group.The control group was treated with daunorubicin and cytarabine,while treatment group was treated with idarubicin and cytarabine.Both groups were treated for 3 weeks.After treatment,curative effect and adverse reactions between the two groups were compared.They were followed up for 1 year to observe survival and recurrence.Results The response rate of treatment in treatment group was significantly higher than that in control group(75.60%vs 53.65%)(P<0.05).There was no significant difference in the incidence of adverse reactions during treatment between the two groups(P>0.05).The survival rates at half a year and 1 year after treatment in treatment group were 87.80% and 60.97%,without significant difference compared with those in control group(70.73%,51.21%)(P>0.05).The recurrence rate at 1 year after treatment in treatment group was significantly higher than that in control group(17.07%vs 36.58%)(P<0.05).Conclusion Idarubicin combined with cytarabine can significantly improve the clinical curative effect on adult patients with AML,and reduce recurrence rate,with high safety.

关 键 词：去甲氧柔红霉素 阿糖胞苷 成人急性髓系白血病 

分 类 号：R733.71[医药卫生—肿瘤]